Colorectal cancer Cancer Malignant neoplasm of rectosigmoid junction
Conditions
Interventions
1. Endoscopy but only as part of routine screening under the National Colorectal Cancer Screening Programme
2. Resection of colorectal cancer by surgery
All patients will receive curcumin 1.8 g daily
Sponsors
University Hospitals of Leicester NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Found to have faecal occult blood (FOB) as part of National Colorectal Cancer Screeing Programme or those awaiting resection of known colorectal cancer 2. Over 18 years of age, either sex 3. Using contraception
Exclusion criteria
Exclusion criteria: 1. History in past year of discrete gastric or duodenal ulcer of size greater than 5 mm 2. Inability to return for follow up tests 3. Significant medical or psychiatric problems (including renal, hepatic or haematological dysfunction) 4. Use of any investigational agent within last 3 months 5. History of pelvic radiation 6. Women of child bearing age unless they agree to provide written confirmation that they are using adequate contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| From 30 eligible patients who are compliant in taking all doses have tissue measurement of curcumin greater than or equal to 5 nMol/g tissue, assessed approximately two months after completion of the trial when the colon biopsies will be assayed in the laboratories for curcumin levels. The exact timing of assay will vary depending on the number of samples which will be batched together for assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the practicality, acceptability and safety of individuals taking 5 capsules of curcumin (2.25 g total daily dose of curcuminoids, 1.8 g curcumin) daily for 14 days, assessed at 3 weeks from entry to the study. | — |
Countries
United Kingdom
Outcome results
None listed